BioVie Inc. (BIVI)

Market Cap	13.35M
Revenue (ttm)	n/a
Net Income (ttm)	-19.36M
Shares Out	7.85M
EPS (ttm)	-16.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	468,332
Open	1.730
Previous Close	1.670
Day's Range	1.650 - 1.810
52-Week Range	1.520 - 75.000
Beta	1.07
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2025

About BIVI

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and chang...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: BIVI
• Website: https://bioviepharma.com